INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,889,773 | -28.9% | 36,279 | -13.6% | 0.02% | -40.6% |
| Q2 2023 | $2,657,920 | +13.9% | 41,976 | -16.3% | 0.03% | -36.0% |
| Q3 2022 | $2,334,000 | +118.3% | 50,158 | +167.8% | 0.05% | +78.6% |
| Q2 2022 | $1,069,000 | +53.6% | 18,727 | +0.3% | 0.03% | +154.5% |
| Q3 2021 | $696,000 | +50.3% | 18,678 | -41.6% | 0.01% | -8.3% |
| Q4 2017 | $463,000 | -51.1% | 31,965 | -46.7% | 0.01% | -50.0% |
| Q3 2017 | $947,000 | -61.0% | 59,991 | -1.1% | 0.02% | -70.7% |
| Q3 2015 | $2,428,000 | +567.0% | 60,637 | +203.2% | 0.08% | +446.7% |
| Q1 2014 | $364,000 | – | 20,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |